Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Basilea
Biotech
Basilea opts not to take MRSA antibiotic into clinic
Basilea has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development.
James Waldron
Feb 18, 2025 4:08am
Basilea scores $268M BARDA funding for antifungals, antibiotics
Sep 19, 2024 7:45am
Basilea continues pipeline refill with Pfizer antifungal
Nov 13, 2023 8:15am
Basilea anti-infective strategy restarts with $2M antifungal buy
Oct 19, 2023 7:25am
Basilea hands back antifungal 9 months after licensing it
Jan 17, 2023 7:15am
BIO CEO out the door—Chutes & Ladders
Oct 14, 2022 9:30am
